{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:23:16Z","timestamp":1786990996019,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115331","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T09:13:33Z","timestamp":1754730813000},"page":"115331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Protein targets & therapeutics in psoriasis: toward personalization"],"prefix":"10.1016","volume":"164","author":[{"given":"Mohammad Abuzar","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyaul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzarul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Taleuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115331_bb0005","first-page":"1","article-title":"The immunology of psoriasis\u2014current concepts in pathogenesis","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.115331_bb0015","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2025.115331_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0025","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0030","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/jid.2010.36","article-title":"Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models","volume":"130","author":"Gudjonsson","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115331_bb0035","doi-asserted-by":"crossref","first-page":"2300437","DOI":"10.1002\/biot.202300437","article-title":"3D-QSAR pharmacophore modeling, virtual screening, molecular docking, MD simulations, in vitro and in vivo studies to identify potential anti-hyperplasia drugs","volume":"19","author":"Khan","year":"2024","journal-title":"Biotechnol. J."},{"issue":"12","key":"10.1016\/j.intimp.2025.115331_bb0040","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.3390\/nano11123433","article-title":"Development and in vitro\/in vivo evaluation of pH-sensitive polymeric nanoparticles loaded hydrogel for the management of psoriasis","volume":"11","author":"Asad","year":"2021","journal-title":"Nanomaterials"},{"issue":"10","key":"10.1016\/j.intimp.2025.115331_bb0045","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1007\/s42250-024-01088-w","article-title":"Exploring the therapeutic potential: MTX\/TAC Nanoformulation in IMQ-induced psoriasis models","volume":"7","author":"Asad","year":"2024","journal-title":"Chem. Afr."},{"key":"10.1016\/j.intimp.2025.115331_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2016.07.039","article-title":"Spread of psoriasiform inflammation to remote tissues is restricted by the atypical chemokine receptor ACKR2","volume":"137","author":"Shams","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.10.022","article-title":"Prokineticin 2 plays a pivotal role in psoriasis","volume":"13","author":"He","year":"2016","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.intimp.2025.115331_bb0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis\u2014current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062347","article-title":"Immunolocalization of the tumor-sensitive calmodulin-like protein CALML3 in normal human skin and hyperproliferative skin disorders","volume":"8","author":"Bennett","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0070","article-title":"Downregulation of TNIP1 expression leads to increased proliferation of human keratinocytes and severer psoriasis-like conditions in an imiquimod-induced mouse model of dermatitis","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0075","doi-asserted-by":"crossref","first-page":"E6162","DOI":"10.1073\/pnas.1606996113","article-title":"Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function","volume":"113","author":"Ippagunta","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076416","article-title":"Karyopherin alpha2 is essential for rRNA transcription and protein synthesis in proliferative keratinocytes","volume":"8","author":"Umegaki-Arao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0085","article-title":"Expression and functional role of Sox9 in human epidermal keratinocytes","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0090","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2025.115331_bb0095","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1038\/jid.2015.231","article-title":"CCN1, a pro-inflammatory factor, aggravates psoriasis skin lesions by promoting keratinocyte activation","volume":"135","author":"Sun","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111255","article-title":"CARD14 expression in dermal endothelial cells in psoriasis","volume":"9","author":"Harden","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0105","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2015.09.055","article-title":"The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases","volume":"137","author":"Harden","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0110","first-page":"40","article-title":"Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris, dermatologic","volume":"66","author":"Guzel","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115331_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jdermsci.2015.05.007","article-title":"Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis","volume":"79","author":"Batycka-Baran","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2017.06.003","article-title":"Psoriasis-associated late cornified envelope (LCE) proteins have antibacterial activity","author":"Niehues","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0125","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115331_bb0130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.yexmp.2011.04.015","article-title":"Significance of DC-LAMP and DC-SIGN expression in psoriasis vulgaris lesions","volume":"91","author":"Wei","year":"2011","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.intimp.2025.115331_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.advms.2015.07.011","article-title":"CXCL10 in psoriasis","volume":"60","author":"Ferrari","year":"2015","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0140","article-title":"Lack of galanin receptor 3 alleviates psoriasis by altering vascularization, immune cell infiltration and cytokine expression","author":"Locker","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.02.014","article-title":"GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model","volume":"33","author":"Nadeem","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2025.115331_bb0150","article-title":"Targeted siRNA therapy for psoriasis: translating preclinical potential into clinical treatments","volume":"259-271","author":"Zhao","year":"2024","journal-title":"ImmunoTargets and Therapy"},{"key":"10.1016\/j.intimp.2025.115331_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11745-016-4211-4","article-title":"Serum fatty acid-binding protein 4 is increased in patients with psoriasis","volume":"52","author":"Baran","year":"2017","journal-title":"Lipids"},{"key":"10.1016\/j.intimp.2025.115331_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9538451","article-title":"Chitinase-3-like protein 1 (YKL-40) is a new biomarker of inflammation in psoriasis","author":"Salomon","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2025.115331_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2024.2387604","article-title":"An overview of Skp2: a promising new therapeutic target of psoriasis","author":"Tomar","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.intimp.2025.115331_bb0170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.bor.0000160781.07174.db","article-title":"New strategies for immunosuppression: interfering with cytokines by targeting the Jak\/Stat pathway","volume":"17","author":"O\u2019Shea","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115331_bb0175","first-page":"198","article-title":"S100 protein family and its application in clinical practice","volume":"12","author":"Sedaghat","year":"2008","journal-title":"Hippokratia"},{"key":"10.1016\/j.intimp.2025.115331_bb0180","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.3390\/ijms140610869","article-title":"Epidermal development in mammals: key regulators, signals from beneath, and stem cells","volume":"14","author":"Liu","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0185","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0344-0338(96)80088-4","article-title":"The role of p53 in cell cycle regulation","volume":"192","author":"Shaw","year":"1996","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.intimp.2025.115331_bb0190","article-title":"The cell: a molecular approach. 2nd edition. Sunderland (MA): Sinauer associates","author":"Cooper","year":"2000","journal-title":"The Central Role of Enzymes as Biological Catalysts."},{"issue":"7","key":"10.1016\/j.intimp.2025.115331_bb0195","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jid.2020.12.015","article-title":"Computational drug repositioning identifies statins as modifiers of prognostic genetic expression signatures and metastatic behavior in melanoma","volume":"141","author":"Wesley","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115331_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115331_bb0205","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/exd.14502","article-title":"Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis","volume":"31","author":"Samuelov","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0210","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/eji.201242740","article-title":"Small molecule inhibitors of ROR\u03b3t: targeting Th17 cells and other applications","volume":"42","author":"Huh","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.smim.2007.10.011","article-title":"Transcriptional regulation of Th17 cell differentiation","volume":"19","author":"Ivanov","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"TH17 lineage differentiation is programmed by orphan nuclear receptors ROR\u03b1 and ROR\u03b3","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2025.115331_bb0225","first-page":"363","article-title":"Current developments and perspectives in psoriasis. JDDG","volume":"21","author":"Sch\u00f6n","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.intimp.2025.115331_bb0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri1807","article-title":"Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells","volume":"6","author":"Dong","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0235","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/701094","article-title":"Overexpression and selectively regulatory roles of IL-23\/IL-17 axis in the lesions of oral lichen planus","volume":"2014","author":"Lu","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2025.115331_bb0240","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115331_bb0245","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/08916934.2016.1166214","article-title":"New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis","volume":"49","author":"Karczewski","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2025.115331_bb0250","series-title":"U.S. Patent No. 9,290,476. Washington, DC: U.S. Patent and Trademark Office","author":"Leonard","year":"2016"},{"key":"10.1016\/j.intimp.2025.115331_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115574","article-title":"Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor \u03b3t (ROR\u03b3t) inverse agonists for autoimmune diseases","volume":"258","author":"Lu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0260","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115331_bb0265","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.C111.250407","article-title":"Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR\u03b3t protein","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2014.04.005","article-title":"The emerging landscape of ROR\u03b3t biology","volume":"40","author":"Lee","year":"2014","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2025.115331_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248034","article-title":"Small molecule allosteric inhibitors of ROR\u03b3t block Th17-dependent inflammation and associated gene expression in vivo","volume":"16","author":"Saenz","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0280","doi-asserted-by":"crossref","first-page":"37977","DOI":"10.1038\/srep37977","article-title":"Pharmacologic modulation of ROR\u03b3t translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis","volume":"6","author":"Xue","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115331_bb0285","doi-asserted-by":"crossref","first-page":"1286344","DOI":"10.3389\/fimmu.2023.1286344","article-title":"Crosstalk: keratinocytes and immune cells in psoriasis","volume":"14","author":"Kamata","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115331_bb0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd4100","article-title":"REV-ERB and ROR nuclear receptors as drug targets","volume":"13","author":"Kojetin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115331_bb0295","first-page":"1","article-title":"Development of a topical treatment for psoriasis targeting ROR\u03b3: from bench to skin","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.intimp.2025.115331_bb0300","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jpha.2023.05.009","article-title":"Small molecule inhibitors of ROR\u03b3t for Th17 regulation in inflammatory and autoimmune diseases","volume":"13","author":"Zeng","year":"2023","journal-title":"J Pharm Anal."},{"key":"10.1016\/j.intimp.2025.115331_bb0305","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1359-6101(03)00019-4","article-title":"TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR\/Fn14 receptor","volume":"14","author":"Wiley","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2025.115331_bb0310","doi-asserted-by":"crossref","first-page":"32401","DOI":"10.1074\/jbc.272.51.32401","article-title":"TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis","volume":"272","author":"Chicheportiche","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0315","first-page":"780","article-title":"Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes","volume":"38","author":"Peternel","year":"2011","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.intimp.2025.115331_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2007.09.007","article-title":"TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK\/Fn14 pathway in health and disease","volume":"40","author":"Burkly","year":"2007","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2025.115331_bb0325","doi-asserted-by":"crossref","first-page":"15395","DOI":"10.1038\/ncomms15395","article-title":"TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis","volume":"8","author":"Sidler","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115331_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0033609","article-title":"TWEAK affects keratinocyte G2\/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus","volume":"7","author":"Sabour Alaoui","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115331_bb0335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cyto.2010.12.003","article-title":"Increased serum TWEAK levels in psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels","volume":"53","author":"Xia","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2025.115331_bb0340","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cyto.2015.10.004","article-title":"Serum levels of TWEAK in patients with psoriasis vulgaris","volume":"77","author":"Bilgic","year":"2016","journal-title":"Cytokine"},{"issue":"65","key":"10.1016\/j.intimp.2025.115331_bb0345","doi-asserted-by":"crossref","first-page":"eabi8823","DOI":"10.1126\/sciimmunol.abi8823","article-title":"TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy","volume":"6","author":"Gupta","year":"2021","journal-title":"Science immunology"},{"key":"10.1016\/j.intimp.2025.115331_bb0350","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.clinthera.2013.06.008","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis","volume":"35","author":"Wisniacki","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2025.115331_bb0355","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/jid.2008.70","article-title":"Roles of aquaporin-3 in the epidermis","volume":"128","author":"Hara-Chikuma","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0360","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/002215549904701007","article-title":"Water channel protein AQP3 is present in epithelia exposed to the environment of possible water loss","volume":"47","author":"Matsuzaki","year":"1999","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.intimp.2025.115331_bb0365","doi-asserted-by":"crossref","first-page":"46616","DOI":"10.1074\/jbc.M209003200","article-title":"Selectively reduced glycerol in the skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery","volume":"277","author":"Hara","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0370","doi-asserted-by":"crossref","first-page":"16140","DOI":"10.1074\/jbc.272.26.16140","article-title":"Water and glycerol permeabilities of aquaporins 1-5 and MIP determined quantitatively by expression of epitope-tagged constructs in Xenopus oocytes","volume":"272","author":"Yang","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0375","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1073\/pnas.1230416100","article-title":"Glycerol replacement corrects defective skin hydration, elasticity, and barrier function in aquaporin-3-deficient mice","volume":"100","author":"Hara","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.115331_bb0380","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00109-007-0272-4","article-title":"Aquaporin-3 facilitates epidermal cell migration and proliferation during wound healing","volume":"86","author":"Hara-Chikuma","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.intimp.2025.115331_bb0385","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/MCB.01482-07","article-title":"Prevention of skin tumorigenesis and impairment of epidermal cell proliferation by targeted aquaporin-3 gene disruption","volume":"28","author":"Hara-Chikuma","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115331_bb0390","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5021\/ad.2001.13.1.7","article-title":"Changes of transepidermal water loss (TEWL) in psoriatic plaques during D-PUVA therapy","volume":"13","author":"Suh","year":"2001","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0395","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1440-0960.2010.00629.x","article-title":"Aquaporin-3 gene and protein expression in sun-protected human skin decreases with skin aging","volume":"51","author":"Li","year":"2010","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0410","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5021\/ad.2012.24.2.168","article-title":"Changes in transepidermal water loss and skin hydration according to expression of aquaporin-3 in psoriasis","volume":"24","author":"Lee","year":"2012","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0415","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbrc.2009.07.077","article-title":"Tumor necrosis factor-alpha decreases aquaporin-3 expression in DJM-1 keratinocytes","volume":"387","author":"Horie","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2025.115331_bb0420","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/jid.2010.395","article-title":"Upregulation of aquaporin-3 is involved in keratinocyte proliferation and epidermal hyperplasia","volume":"131","author":"Nakahigashi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0425","first-page":"6239","article-title":"The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells","volume":"59","author":"Gong","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115331_bb0435","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.intimp.2025.115331_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0625.1994.tb00260.x","article-title":"Expression of epsilon BP, a beta-galactoside-binding soluble lectin, in normal and neoplastic epidermis","volume":"3","author":"Konstantinov","year":"1994","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0445","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2011.07.008","article-title":"Galectin-3 and the skin","volume":"64","author":"Larsen","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2025.115331_bb0450","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.intimp.2025.115331_bb0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","article-title":"Galectin-3\u2014a jack-of-all-trades in cancer","volume":"313","author":"Newlaczyl","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0460","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.3996","article-title":"Psoriasis in humans is associated with down-regulation of galectins in dendritic cells","volume":"228","author":"de la Fuente","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2025.115331_bb0465","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14712\/fb2006052010010","article-title":"Glycophenotype of psoriatic skin","volume":"52","author":"Lacina","year":"2006","journal-title":"Folia Biol."},{"key":"10.1016\/j.intimp.2025.115331_bb0470","first-page":"193","article-title":"Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus, arthritis","volume":"67","author":"Shi","year":"2015","journal-title":"Rheumatol"},{"key":"10.1016\/j.intimp.2025.115331_bb0475","article-title":"Decrease of galectin-3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis","author":"Shi","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.115331_bb0480","doi-asserted-by":"crossref","DOI":"10.1517\/14728214.2012.672559","article-title":"Amyloid beta (Abeta) peptide modulators and other current treatment strategies for Alzheimer\u2019s disease (AD)","author":"Lukiw","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.intimp.2025.115331_bb0485","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.12675","article-title":"Insights into the physiological function of the beta-amyloid precursor protein: beyond Alzheimer\u2019s disease","volume":"129","author":"Dawkins","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.intimp.2025.115331_bb0490","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.0022-202X.2004.23320.x","article-title":"Normalized proliferation of normal and psoriatic keratinocytes by suppression of sAPP\u03b1-release","volume":"123","author":"Siemes","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fneur.2012.00005","article-title":"Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis","volume":"3","author":"Clos","year":"2012","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2025.115331_bb0500","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1073\/pnas.93.7.2749","article-title":"Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding","volume":"93","author":"Botos","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.115331_bb0505","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1471-4159.2007.04685.x","article-title":"Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin","volume":"102","author":"Hiraoka","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.intimp.2025.115331_bb0510","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1078\/0171-9335-00401","article-title":"Biological roles of APP in the epidermis","volume":"83","author":"Herzog","year":"2004","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.intimp.2025.115331_bb0515","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1111\/febs.13831","article-title":"Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs","volume":"283","author":"Lee","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2025.115331_bb0520","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.str.2011.11.016","article-title":"Structures of adnectin\/protein complexes reveal an expanded binding footprint","volume":"20","author":"Ramamurthy","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.intimp.2025.115331_bb0525","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jmb.2008.11.053","article-title":"Structure\u2013function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant","volume":"385","author":"Mukai","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115331_bb0530","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/acs.jmedchem.9b00533","article-title":"Identification of 2-imidazopyridine and 2-aminopyridone purinones as potent pan-janus kinase (JAK) inhibitors for the inhaled treatment of respiratory diseases","volume":"62","author":"Bach","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0535","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.bmcl.2008.01.093","article-title":"Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives","volume":"18","author":"Costanzo","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0540","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S, 5R)-5-((7H-Pyrrolo [2, 3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl) prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0545","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1021\/bi982483d","article-title":"Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+\u2212bound human psoriasin (S100A7) in the Zn2+\u2212loaded and Zn2+\u2212free states","volume":"38","author":"Brodersen","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2025.115331_bb0550","doi-asserted-by":"crossref","first-page":"13220","DOI":"10.1021\/bi034653e","article-title":"The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis","volume":"42","author":"Huai","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2025.115331_bb0555","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1016\/j.bmcl.2011.09.109","article-title":"Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2","volume":"21","author":"Nankervis","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0560","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/jm301646k","article-title":"3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models","volume":"56","author":"Soth","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0565","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bmcl.2009.11.021","article-title":"A novel chemotype of kinase inhibitors: discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0570","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.bmcl.2013.08.082","article-title":"Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1\/2 inhibitors","volume":"23","author":"Labadie","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0575","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115331_bb0580","series-title":"Crystal structure of human Cathepsin-S with bound ligand. Protein Data Bank, PDB ID: 5QC5","author":"Bembenek","year":"2025"},{"key":"10.1016\/j.intimp.2025.115331_bb0585","article-title":"Biphenyl pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships","author":"Cabedo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0590","doi-asserted-by":"crossref","first-page":"30859","DOI":"10.1038\/srep30859","article-title":"Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115331_bb0595","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2016.04.008","article-title":"Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC\u03b8 inhibitors","volume":"24","author":"Katoh","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0600","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bmcl.2015.01.032","article-title":"Potent and selective Bruton\u2019s tyrosine kinase inhibitors: discovery of GDC-0834","volume":"25","author":"Young","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0605","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1215904","article-title":"Crystal structure of a lipid G protein\u2013coupled receptor","volume":"335","author":"Hanson","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115331_bb0610","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.str.2011.11.016","article-title":"Structures of adnectin\/protein complexes reveal an expanded binding footprint","volume":"20","author":"Ramamurthy","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.intimp.2025.115331_bb0615","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1215904","article-title":"Crystal structure of a lipid G protein\u2013coupled receptor","volume":"335","author":"Hanson","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115331_bb0620","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115331_bb0625","series-title":"Structure of full length human ampk (non-phosphorylated at t-loop) in complex with a small molecule activator, a benzimidazole derivative (991). Protein data bank, pdb id: 5iso","author":"Xiao","year":"2025"},{"key":"10.1016\/j.intimp.2025.115331_bb0630","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1021\/acs.jmedchem.1c02058","article-title":"Discovery and structural optimization of toddacoumalone derivatives as novel PDE4 inhibitors for the topical treatment of psoriasis","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0635","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41594-018-0108-7","article-title":"Structure and gating mechanism of the transient receptor potential channel TRPV3","volume":"25","author":"Singh","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115331_bb0640","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.cell.2016.05.040","article-title":"Breaking cryo-EM resolution barriers to facilitate drug discovery","volume":"165","author":"Merk","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115331_bb0645","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jid.2017.05.036","article-title":"Characterization of autoantigen presentation by HLA-C* 06:02 in psoriasis","volume":"137","author":"Wei","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115331_bb0650","series-title":"Conformational changes in the (ala-84-val) mutant of tumor necrosis factor. Protein Data Bank, PDB ID: 2TUN","author":"Saludjian","year":"2025"},{"key":"10.1016\/j.intimp.2025.115331_bb0655","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jb\/mvp065","article-title":"Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists","volume":"146","author":"Mukai","year":"2009","journal-title":"J. Biochem."},{"key":"10.1016\/j.intimp.2025.115331_bb0660","doi-asserted-by":"crossref","first-page":"17595","DOI":"10.1016\/S0021-9258(18)71533-0","article-title":"The structure of tumor necrosis factor-\u03b1 at 2.6 \u00c5 resolution: implications for receptor binding","volume":"264","author":"Eck","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0665","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1074\/jbc.273.4.2153","article-title":"High resolution crystal structure of a human tumor necrosis factor-\u03b1 mutant with low systemic toxicity","volume":"273","author":"Cha","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0670","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/protein\/10.10.1101","article-title":"Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2","volume":"10","author":"Reed","year":"1997","journal-title":"Protein Eng."},{"key":"10.1016\/j.intimp.2025.115331_bb0675","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M707933200","article-title":"Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-\u03b1 antagonist","volume":"283","author":"Shibata","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115331_bb0680","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1093\/emboj\/16.23.7078","article-title":"Structure of the human NF-\u03baB p52 homodimer-DNA complex at 2.1 \u00c5 resolution","volume":"16","author":"Cramer","year":"1997","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115331_bb0685","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor a","volume":"4","author":"Liu","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2025.115331_bb0690","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jmb.2008.08.001","article-title":"Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody","volume":"382","author":"Beyer","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115331_bb0695","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/pro.3862","article-title":"X-ray crystal structure localizes the mechanism of inhibition of an IL-36R antagonist monoclonal antibody to interaction with Ig1 and Ig2 extra cellular domains","volume":"29","author":"Larson","year":"2020","journal-title":"Protein Sci."},{"issue":"12","key":"10.1016\/j.intimp.2025.115331_bb0700","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115331_bb0705","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Mechanisms of disease: psoriasis","volume":"361","author":"Frank","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115331_bb0710","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jid.2022.02.016","article-title":"IL-17A promotes psoriasis-associated keratinocyte proliferation through ACT1-dependent activation of YAP\u2013AREG axis","volume":"142","author":"Yu","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"13","key":"10.1016\/j.intimp.2025.115331_bb0715","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.3390\/ijms22136740","article-title":"From messengers to receptors in psoriasis: the role of IL-17RA in disease and treatment","volume":"22","author":"Vidal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10275","key":"10.1016\/j.intimp.2025.115331_bb0720","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.intimp.2025.115331_bb0725","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115331_bb0730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:49:35Z","timestamp":1772891375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925013220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":143,"alternative-id":["S1567576925013220"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115331","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein targets & therapeutics in psoriasis: toward personalization","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115331"}}